Burdett N, et al. - In older adults, cancer comorbidities may have as much an impact on survival and quality of life as any malignancy, so considering competing risk is important in the design and reporting of geriatric oncology trials. Researchers undertook a systematic review of phase 2 and 3 oncology trials for systemic therapy in older patients with solid organ malignancy from the year 2000 until April 30, 2017. They identified only 15 trials that employed disease-related endpoints to account for death from other causes, and only one study that used statistical analysis addressing competing risk. Some assessment of comorbidity or frailty were included in seventeen studies of trials. In 21 trials, any assessment of quality of life was included. These results suggest a clear need for improvement in future studies in considering trial design, data collection, and suitable statistical methodology for describing competing risks in geriatric oncology trials.